~ Third Quarter 2026 Net Product Sales of $19.4 Million, Up 56% Year over Year ~
~ Third Quarter 2026 Non-GAAP Adjusted EBITDA of $5.8 Million ~
~ With $6.7 Million in Positive Cash Flow from Operations, Cash Position in the Third Quarter 2026 Grew to $48.7 Million ~
~ Record Number of Patients and Planned Infusions Carried into the Fourth Quarter 2026 ~
~ Management to Host Conference Call Today at 8:30 a.m. ET ~
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the third quarter ended September 30, 2026 and provided a business update.
“Given the significant increase in demand that we are seeing quarter over quarter in 2026, we firmly believe in the sustainable growth potential of PEDMARK®. We are driving this forward through strong commercial execution, investment in evidence generation to support its use, and operational enhancements that will continue to improve the overall patient and healthcare professional experience,” said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. “Additionally, with net revenue, adjusted EBITDA, and our cash position reaching record highs this quarter, we will continue to be disciplined in our capital deployment as we move through the fourth quarter and look ahead to 2027.”
Business Highlights:
- Continued Commercial Momentum Within Key PEDMARK® Accounts: The second full quarter following the significant expansion of our commercial organization contributed to another sequential quarter of demand growth, with total program enrollments up 23% and completed infusions up 58% over the second quarter of 2026. As the field team is now operating with greater reach and frequency to engage healthcare providers, Fennec expects that the productivity curve will continue to increase through the fourth quarter of 2026 and into 2027.
- 58th Annual International Society of Pediatric Oncology (SIOP) Annual Meeting: Detailed results from the investigator-initiated Phase 2 STS-J01 clinical trial evaluating PEDMARK® for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan were featured in an oral presentation at SIOP 2026. These data demonstrated significant hearing protection and provide reassuring clinical context regarding antitumor activity with delayed PEDMARK® administration. Full results from the study will be submitted for peer-reviewed publication.
Upcoming Events:
- 17th Annual Craig-Hallum Alpha Select Conference: The management team will host one-on-one investor meetings at the 17th Annual Craig-Hallum Alpha Select Conference, which will be held on Tuesday, November 17, 2026 at the Sheraton New York Times Square Hotel in New York City.
- Piper Sandler 38th Annual Healthcare Conference: The management team will participate in a fireside chat on Thursday, December 3, 10:30 – 10:55 a.m. ET, at the conference and will host one-on-one investor meetings, which will be held at the Lotte New York Palace and will be available via webcast.
Financial Results for the Third Quarter Ended September 30, 2026:
- Net Product Sales – For the third quarter of 2026, the Company recorded net product sales of approximately $19.4 million compared to $12.5 million in the third quarter of 2025. The increase in sales is attributable to growth across PEDMARK® accounts including new accounts in the AYA population.
- Selling and Marketing Expenses – The Company recorded $10.1 million in selling and marketing expenses in the third quarter of 2026 compared to $6.5 million in the third quarter of 2025. The increase is largely related to the higher costs associated with the commercialization and increased awareness initiatives of PEDMARK® and related expenses to support the expansion of our sales organization.
- General and Administrative (G&A) Expenses – The Company recorded $3.9 million in general and administrative expenses in the third quarter of 2026 compared to $5.4 million in the third quarter of 2025. The decrease in general and administrative expenses for the three-month comparable periods due to lower legal and professional fees as select litigation activities concluded.
- Non-GAAP Adjusted EBITDA – The Company recorded $5.8 million in non-GAAP adjusted EBITDA in the third quarter of 2026 compared to non-GAAP adjusted EBITDA of $2.0 million for the same period in the prior year. A table reconciling non-GAAP measures is included in this press release for reference.
- Cash Position – Cash and cash equivalents were $48.7 million as of September 30, 2026 compared to $41.2 million as of June 30 2026. We anticipate that our cash, cash equivalents and investment securities as of September 30, 2026, combined with the projected revenues from PEDMARK®, will be sufficient to fund our business based on our current operating plan.
Third Quarter 2026 Conference Call Information
Date: Thursday, November 12, 2026
Time: 8:30 a.m. Eastern Time
Webcast Link: https://edge.media-server.com/mmc/p/vuhn59ek
Participant Link: https://register-conf.media-server.com/register/BIa5435e66b82346329a08be7e156e3eac
Financial Update
The selected financial data presented below is derived from our unaudited condensed consolidated financial statements, which were prepared in accordance with U.S. generally accepted accounting principles. The complete unaudited condensed consolidated financial statements for the period ended September 30, 2026, and management’s discussion and analysis of financial condition and results of operations will be available via www.sec.gov and www.sedar.com. All values are presented in thousands unless otherwise noted.
| Unaudited Condensed Consolidated Statements of Operations (U.S. Dollars in thousands except share and per share amounts) |
|||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | September 30, | September 30, | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue | |||||||||||||||
| PEDMARK product sales, net | $ | 19,425 | $ | 12,462 | $ | 51,697 | $ | 30,865 | |||||||
| Other revenue | 183 | — | 893 | — | |||||||||||
| Total revenue | 19,608 | 12,462 | 52,590 | 30,865 | |||||||||||
| Operating expenses: | |||||||||||||||
| Cost of product sales | 838 | 660 | 2,129 | 2,000 | |||||||||||
| Research and development | 154 | 29 | 321 | 230 | |||||||||||
| Selling and marketing | 10,050 | 6,513 | 32,131 | 12,510 | |||||||||||
| General and administrative | 3,912 | 5,449 | 11,737 | 19,853 | |||||||||||
| Total operating expenses | (14,954 | ) | (12,651 | ) | (46,318 | ) | (34,593 | ) | |||||||
| Income/(loss) from operations | 4,654 | (189 | ) | 6,272 | (3,728 | ) | |||||||||
| Other (expense)/income | |||||||||||||||
| Unrealized foreign exchange (loss)/gain | — | (3 | ) | (18 | ) | 27 | |||||||||
| Amortization expense | — | (12 | ) | — | (38 | ) | |||||||||
| Interest income | 319 | 152 | 945 | 559 | |||||||||||
| Interest expense | (1 | ) | (586 | ) | (11 | ) | (1,772 | ) | |||||||
| Total other income/(expense) | 318 | (449 | ) | 916 | (1,226 | ) | |||||||||
| Income/(loss) before provision for income taxes | 4,972 | (638 | ) | 7,188 | (4,954 | ) | |||||||||
| Provision for income taxes | 332 | — | 374 | — | |||||||||||
| Net income/(loss) | $ | 4,640 | $ | (638 | ) | $ | 6,814 | $ | (4,954 | ) | |||||
| Basic net income/(loss) per common share | $ | 0.13 | $ | (0.02 | ) | $ | 0.20 | $ | (0.18 | ) | |||||
| Diluted net income/(loss) per common share | $ | 0.12 | $ | (0.02 | ) | $ | 0.19 | $ | (0.18 | ) | |||||
| Weighted-average number of common shares outstanding basic | 35,112 | 27,889 | 34,772 | 27,711 | |||||||||||
| Weighted-average number of common shares outstanding diluted | 38,076 | 27,889 | 36,679 | 27,711 | |||||||||||
| Fennec Pharmaceuticals Inc. Unaudited Condensed Consolidated Balance Sheets (U.S. Dollars and shares in thousands) |
||||||||
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 48,684 | $ | 36,788 | ||||
| Accounts receivable, net | 23,786 | 23,221 | ||||||
| Prepaid expenses | 4,948 | 3,738 | ||||||
| Inventory | 2,117 | 1,565 | ||||||
| Other current assets | 1,416 | 1,731 | ||||||
| Total current assets | 80,951 | 67,043 | ||||||
| Non-current assets | ||||||||
| Non-current accounts receivable, net | 1,952 | 2,791 | ||||||
| Other non-current assets, net of amortization | 640 | 717 | ||||||
| Total non-current assets | 2,592 | 3,508 | ||||||
| Total assets | $ | 83,543 | $ | 70,551 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,607 | $ | 4,635 | ||||
| Accrued liabilities | 5,830 | 5,635 | ||||||
| Contract liability-current | 2,807 | 248 | ||||||
| Total current liabilities | 13,244 | 10,518 | ||||||
| Long-term liabilities | ||||||||
| Contract liability – long-term | 21,109 | 24,561 | ||||||
| Total long-term liabilities | 21,109 | 24,561 | ||||||
| Total liabilities | 34,353 | 35,079 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock, no par value; unlimited shares authorized; 35,215 shares issued and outstanding (2025 ‑34,163) | 194,093 | 189,906 | ||||||
| Additional paid-in capital | 76,462 | 73,745 | ||||||
| Accumulated deficit | (222,608 | ) | (229,422 | ) | ||||
| Accumulated other comprehensive income | 1,243 | 1,243 | ||||||
| Total stockholders’ equity | 49,190 | 35,472 | ||||||
| Total liabilities and stockholders’ equity | $ | 83,543 | $ | 70,551 | ||||
| Reconciliation of Net Income/(Loss) to Adjusted EBITDA (Non-GAAP) (U.S. Dollars in thousands) |
|||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | September 30, | September 30, | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net income/(loss) | $ | 4,640 | $ | (638 | ) | $ | 6,814 | $ | (4,954 | ) | |||||
| Interest income | (319 | ) | (152 | ) | (945 | ) | (559 | ) | |||||||
| Interest expense | 1 | 586 | 11 | 1,772 | |||||||||||
| Provision for income taxes | 332 | – | 374 | – | |||||||||||
| Depreciation and amortization | – | 12 | – | 38 | |||||||||||
| Other revenue (a) | (183 | ) | – | (893 | ) | – | |||||||||
| Share based compensation expense (b) | 1,355 | 2,219 | 4,119 | 4,511 | |||||||||||
| Unrealized loss on securities | – | – | – | 2 | |||||||||||
| Unrealized foreign exchange gain/(loss) | – | 3 | 18 | (27 | ) | ||||||||||
| Adjusted EBITDA | $ | 5,826 | $ | 2,030 | $ | 9,498 | $ | 783 | |||||||
(a) Represents the portion of GAAP revenue related to “material rights” under the Company’s PEDMARK® license with Norgine that is non-cash in the current period and was previously recorded as deferred licensing revenue. Under ASC 606, a portion of the upfront consideration received under this agreement was allocated to a material right and recorded as deferred revenue (contract liability), which is subsequently recognized as revenue as PEDMARK® units are shipped to Norgine and the related material right is satisfied. These amounts are included in GAAP revenue in the periods presented, and the Company continues to apply GAAP recognition and measurement for all revenue, including this component. The adjustment is intended solely to remove this non-cash amortization of previously deferred licensing revenue from Adjusted EBITDA, as management believes excluding this item provides a more comparable view of period-over-period cash operating performance from the Company’s commercial activities.
(b) Represents share-based compensation expense to account for stock options, restricted stock, and other stock awards over their respective vesting periods.
About Cisplatin-Induced Ototoxicity
Cisplatin and other platinum-based chemotherapies are widely used to treat solid tumors and have been vital in improving survival rates. Unfortunately, these life-saving treatments often result in permanent, irreversible hearing loss, also known as ototoxicity.1
Hearing loss from cisplatin treatment is not rare. Studies show that between 60-90% of patients treated with cisplatin may develop hearing loss, depending upon the dose and duration of chemotherapy.2 Many of those treated with cisplatin will require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time.3 Treatment-induced hearing loss can reduce quality of survivorship as it impacts many aspects of life, such as speech and language skills, academic performance, social-emotional development, career potential and the ability to live independently.4,5 While audiologic monitoring is recommended to help manage ototoxicity, it is currently underutilized in certain cancer patient populations.
PEDMARK® (sodium thiosulfate injection)
PEDMARK® is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients 1 month of age and older with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the first and only therapeutic agent with proven efficacy and safety data with an established dosing regimen, across two open-label, randomized Phase 3 clinical studies, the Children’s Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.
Additionally, PEDMARK® is recommended for the adolescent and young adult (AYA) population by the National Comprehensive Cancer Network, or NCCN, with a 2A endorsement.
Approximately 500,000 patients in the U.S. are diagnosed annually with cancers that could be treated with a platinum-based chemotherapy.6,7 The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of those treated will require lifelong hearing aids. Until the FDA approval of PEDMARK, there were no preventative agents for this hearing loss. Patients with hearing loss resulting from cancer treatment have a statistically significant worse quality of life compared with peers who have no hearing loss.8,9
PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Indications and Usage
PEDMARK® (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.
Limitations of Use
The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.
Important Safety Information
PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.
Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.
PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.
Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium levels at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.
Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m2.
Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.
The most common adverse reactions (≥25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.
Please see full Prescribing Information for PEDMARK® at: www.PEDMARK.com.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI®.
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in multiple countries.
PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.
For more information, please visit www.fennecpharma.com and follow on LinkedIn.
Forward Looking Statements
Except for historical information described in this press release, all other statements are forward-looking. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about our business strategy, timeline and other goals, plans and prospects, including our commercialization plans respecting PEDMARK®/PEDMARQSI®, the market opportunity for and market impact of PEDMARK®/ PEDMARQSI®, its potential impact on patients and anticipated benefits associated with its use, future commercial and regulatory milestone and royalty payments from Norgine, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, our ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2025. Fennec disclaims any obligation to update these forward-looking statements except as required by law.
For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.
PEDMARK® PEDMARQSI® and Fennec® are registered trademarks of Fennec Pharmaceuticals Inc.
©2026 Fennec Pharmaceuticals Inc. All rights reserved.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
_______________
1 Sheth S et al. Mechanisms of Cisplatin Ototoxicity and Progress in Otoprotection. Frontiers in Cellular Neuroscience. 2017, Vol. 11.
2 Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013;34(8):458-469
3 Landier W. Ototoxicity and Cancer Therapy. Cancer. June 2016 Vol. 122, No.11: 1647-1658.
4 Clemens E, van den Heuvel-Eibrink MM, Mulder RL, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol. 2019;20(1):e29-e41
5 Bass JK, Knight KR, Yock TI, Chang KW, Cipkala D, Grewal SS. Evaluation and management of hearing loss in survivors of childhood and adolescent cancers: a report from the children’s oncology group. Pediatr Blood Cancer. 2016;63(7):1152-1162.
6 Chattaraj A et al. Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies. JCO Oncol Pract. 2023;19
7 Freyer DR et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(1):63-74.
8 Rajput K, Edwards L, Brock P, Abiodun A, Simpkin P, Al-Malky G. Ototoxicity-induced hearing loss and quality of life in survivors of paediatric cancer. Int J Pediatr Otorhinolaryngol. 2020;138:110401. doi:10.1016/j.ijporl.2020.110401
9 Bass JK, Knight KR, Yock TI, Chang KW, Cipkala D, Grewal SS. Evaluation and management of hearing loss in survivors of childhood and adolescent cancers: a report from the children’s oncology group. Pediatr Blood Cancer. 2016;63(7):1152-1162.
